πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 19 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12427148

Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

The Regents of the University of California Β· Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12420113

Methods and apparatus for applying tumor treating fields combined with personalized ultra-

The Board of Regents of the University of Texas System Β· Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12266425

T cell receptor sequences diagnostic for COVID-19 and related compositions

Adaptive Biotechnologies Corporation Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264187

Compositions and methods for targeted therapeutic delivery to bone

Theradaptive, Inc. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12263179

Lyme disease-associated T cell receptor-related methods

Adaptive Biotechnologies Corporation Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12054744

NK cells exhibiting an adaptive phenotype and methods for preparing and for using

Regents of the University of Minnesota Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12006517

Method for purification of bacteriophage particles

Adaptive Phage Therapeutics, Inc. Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11911345

Phage dispensing system

Adaptive Phage Therapeutics, Inc. Β· Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11826422

Methods and compositions for adaptive immune modulation

The Board of Regents of the University of Texas System Β· Granted Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11773138

Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof

Theradaptive, Inc. Β· Granted Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11390921

Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)

Adaptive Biotechnologies Corporation Β· Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11253522

Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

The Regents of the University of California Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11192923

Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof

Theradaptive, Inc. Β· Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11191780

Extracellular matrix compositions for the treatment of cancer or immunological diseases

Adaptive Biologix, Inc. Β· Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11041202

Method of identifying human compatible T cell receptors specific for an antigenic target

Adaptive Biotechnologies Corporation Β· Granted Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11026969

High affinity T cell receptors and uses thereof

Adaptive Biotechnologies Corporation Β· Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10995317

NK cells exhibiting an adaptive phenotype and methods for preparing and for using

Regents of the University of Minnesota Β· Granted Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10875903

Bifunctional fusion proteins to inhibit angiogenesis in tumor microenvironment and to acti

CHINA PHARMACEUTICAL UNIVERSITY Β· Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10675303

Extracellular matrix compositions for the treatment of cancer

Adaptive Biologix, Inc. Β· Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted